Barcelona, February 2015. Sagetis is pleased to announce that the Japanese Patent office has issued notice of allowance of a patent covering one of the biodegradable polymers of its current portfolio. This announcement follows the previous grant of the same patent by the USPTO in 2014.
The patent is in force through 2028 and covers 21 claims. It was in-licensed from IQS in 2011 and covers the description of a new biocompatible polymer - currently being used in NanoBBB and BoneTack platforms - and represents a significant milestone in Sagetis’ patent strategy. The company is still prosecuting this patent application in Europe and Canada.
About Sagetis Biotech
At Sagetis Biotech we are devoted to developing innovative drug delivery technologies to tackle challenging unmet medical needs. Based in Barcelona, Sagetis Biotech was founded in 2010 as a spin-off from GEMAT (Materials Engineering Group) at IQS.
The company's versatile, polymeric-based platforms are designed to tackle highly challenging areas, such as (i) delivery through difficult-to-cross barriers(e.g. blood-brain barrier, intestinal mucus gel layer, ocular); (ii) efficient transfection of genetic material, using both viral and non-viral vectors.